Does the Market Like AVEO Stock After it Has Risen 7.14% in a Week?

Tuesday, November 12, 2019 9:48 AM | InvestorsObserver Analysts

AVEO Pharmaceuticals, Inc. (AVEO) stock is up 7.14% over the past week and gets a Neutral rating from InvestorsObserver's Sentiment Indicator.

Click Here to get the full Stock Score Report on AVEO Pharmaceuticals, Inc. (AVEO) Stock.

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score.

As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend.

Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor.

InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon.

The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With AVEO Stock Today?

AVEO Pharmaceuticals, Inc. (AVEO) stock is higher by 17.42% while the S&P 500 is flat 0% as of 9:45 AM on Tuesday, Nov 12. AVEO has risen $0.09 from the previous closing price of $0.52 on volume of 1,414,436 shares. Over the past year the S&P 500 is up 13.23% while AVEO has fallen -66.67%. AVEO lost -$0.04 per share in the over the last 12 months.

To see the top 5 stocks in the Biotechnology industry click here.

Share this article:

Related Companies

Upgrade to Premium and Analyze Stocks Like a Pro

40% Off All Subscriptions
InvestorsObserver Premium
InvestorsObserver Premium
InvestorsObserver Premium
Save up to 57% with annual

InvestorsObserver Premium

$ 20.75 $ 12.45 /month
$249 $149.40 billed annually

You May Also Like

Related Articles

Sector Update: Biotechs Drag Health Care Stocks Lower

Stocks Poised to Close Higher Friday on COVID-19 Treatment Optimism

Sector Update: Health Care

Is Price of INO Stock Justified by its Earnings?

Related Companies